Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound.
about
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateBAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors.
P2860
Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@en
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@nl
type
label
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@en
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@nl
prefLabel
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@en
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@nl
P2093
P2860
P356
P1476
Unexpected Potency Differences ...... r, 60-Mer, and Membrane-Bound.
@en
P2093
Amy M Nicoletti
Ashraf M Khalil
Cynthia Hess Kenny
David H Presky
Julie Ritchie
Kerry L M Ralph
Sathyadevi Venkataramani
Scott M DeWire
Scott R Brodeur
P2860
P356
10.1124/JPET.116.236075
P407
P577
2016-07-20T00:00:00Z